Type / Class
Equity / American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share
Shares outstanding
41.1M
Number of holders
22
Total 13F shares, excl. options
24.3M
Shares change
+1.39M
Total reported value, excl. options
$24.8M
Value change
+$1.85M
Number of buys
7
Number of sells
-12
Price
$1.02

Significant Holders of Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share (ACHL) as of Q3 2024

31 filings reported holding ACHL - Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share as of Q3 2024.
Achilles Therapeutics plc - American Depositary Shares, each representing one ordinary share, nominal value of 0.001 per share (ACHL) has 22 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 24.3M shares of 41.1M outstanding shares and own 59.19% of the company stock.
Largest 10 shareholders include Syncona Portfolio Ltd (11.1M shares), BML Capital Management, LLC (4.1M shares), FCPM III SERVICES B.V. (2.39M shares), Redmile Group, LLC (1.61M shares), Vestal Point Capital, LP (1.5M shares), Ikarian Capital, LLC (1.44M shares), Siren, L.L.C. (755K shares), RENAISSANCE TECHNOLOGIES LLC (638K shares), BOOTHBAY FUND MANAGEMENT, LLC (420K shares), and ACADIAN ASSET MANAGEMENT LLC (251K shares).
This table shows the top 22 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
Investor Option Weight % Change % Value $ * Price $ Shares Share Change Activity Report Period
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.